Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 160 countries through 40* subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market.

* Since March 2012.

Website: www.biomerieux.com
2011: Strengthening our fundamentals to build the future
In 2011, despite a challenging economic environment, bioMérieux delivered a solid operating performance that attests to the strength and solidity of our business model.

Thanks to the dedication of our teams, we achieved an increase of 6.5% in net sales at constant exchange rates (including 4.1% organic growth), with operating income before non-recurring items reaching 18% of sales, in line with our objectives.

This solid performance illustrates the effectiveness of our strategic positioning, which we reaffirm today and base on three tangible assets:

- our undisputed leadership in clinical and industrial microbiology,
- our exceptional global sales network and strong presence in emerging countries, which enable the Group to seize growth opportunities worldwide,
- our innovation capabilities bolstered by our longstanding expertise in biology, as well as a focus on science and medicine.

In 2011, we strengthened our fundamentals by acquiring two companies – AES Laboratoire, in industrial microbiology, and ARGENE, in molecular biology – and by achieving double-digit sales growth in over 10 countries. In addition, we launched 25 new products across all product lines.

Drawing on our extensive experience in biology, bioMérieux is preparing the future with a promising portfolio of innovative systems under development, while also embracing the diagnostic technologies of tomorrow, such as sequencing and mass spectrometry. The Group’s priority focus on innovation is made possible by significant investment in R&D, amounting to about 11% of our net sales, which is higher than average for companies in the in vitro diagnostics industry.

2012 will be a very productive year, with the launch of the new generation VIDAS®, which is particularly well-suited to emerging markets, the development of four other systems that will bring added-value, the ongoing integration of AES Laboratoire and ARGENE, and the creation of two new international commercial subsidiaries.

In-house, we have launched a number of initiatives to optimize our processes and performance. We put in place franchises dedicated to each of our activities, created an R&D Council, whose role is to reinforce the alignment of our research with our strategic and operational objectives, and implemented an internal system for measuring and fostering employee engagement.

In vitro diagnostics is a promising market, and we have undeniable strengths that will help us to carry out a strategy clearly centered on infectious diseases, cardiovascular emergencies and targeted cancers. bioMérieux is determined to play a pioneering role in this field by innovating and designing the diagnostics of the future to meet the major challenges of global public health.

Jean-Luc Belingard
Chairman and CEO
2011 RESULTS AND MILESTONES

SOLID FINANCIAL PERFORMANCE

Sales growth (1)

Net sales for 2011 amounted to €1,427 million, up 5.2% from the €1,357 million generated in 2010. This represented a year-on-year increase of 6.5% at constant exchange rates, including 4.1% growth at constant exchange rates and comparable business base (excluding the impact of recent acquisitions and of discontinuing culture media for routine clinical testing in North America).

Sales of clinical applications (82% of bioMérieux sales) increased by 4% over the year. Microbiology, representing 52% of consolidated sales, advanced 8.2%. The two flagship lines, VITEK® and BacT/ALERT®, performed well during the year, while the success of more recent solutions was confirmed. These include the FMLA® (2) line and the VITEK® MS system. In immuno-assays, the VIDAS® range, which celebrated its 20th anniversary, recorded satisfactory growth of nearly 4%, reflecting the improvement in its strategic positioning: emerging markets and high medical value assays.

Industrial application sales (18% of bioMérieux sales) rose 4.5% over the year. Growth was solid in the Emerging 7 (3) (up 9.2%) and in certain European countries.

Reagents and services accounted for 87.4% of total revenue, increasing by 4.3%. (4)

Instrument sales gained nearly 8%, driven mainly by vigorous demand in emerging markets. They accounted for 12.6% of total revenue. The installed base grew strongly over the year. At December 31, 2011 it had reached close to 65,000 instruments.

Profitability

bioMérieux delivered a solid operating performance in a difficult economic environment in 2011. Operating income before non-recurring items (5) reached €258 million, in line with the objective set by the Group, and represented 18% of sales.

Other financial highlights

bioMérieux generated free cash flow, before acquisitions and dividends, of €118 million, a robust €38 million increase over 2010. Net debt was €131 million at December 31, 2011 and represented 12% of equity.

2012 objectives

In 2012, bioMérieux expects that 2011 trends will continue and has targeted sales growth between 3% and 5% for the year, at constant exchange rates and comparable business base. This objective excludes the impact of the Dima Diagnostika sale and, until July 2012, that of the AES Laboratoire and ARGENE acquisitions, which could add another 3% in growth for the year.

2012 will be a key year in bioMérieux’s development, with the launch of the new generation of its VIDAS platform, the continued development of four other innovative systems, the ramping up of its Services business and the creation of new commercial subsidiaries. The Company will also pursue its transformation plan, in particular with the accelerated deployment of the global ERP system and the introduction of major operating initiatives. Based on these factors, as well as a likely negative currency effect, bioMérieux has targeted operating income before non-recurring items between €255 million and €270 million for the year.

(1) Unless indicated otherwise, growth in sales is at constant exchange rates and scope of consolidation.
(2) Full Microbiology Laboratory Automation.
(3) Brazil, China, India, Indonesia, Mexico, Russia, Turkey.
(4) At constant exchange rates and excluding the end of the South African contract.
(5) Operating income before “material, extraordinary and non-recurring items”, which are included in “other non-recurring operating income and expenses”. 
STATEGIC MILESTONES

2 acquisitions:
AES Laboratoire, a leading French group specialized in industrial microbiological control. The acquisition has made bioMérieux the world leader in agri-food applications.
ARGENE, a French company specialized in molecular biology. Its comprehensive range of diagnostics for immunocompromised patients reinforces bioMérieux’s infectious disease product portfolio.

Equity interest:
bioMérieux also increased its equity interest in sequencing specialist Knome by $5 million as part of a new share issue in July 2011.

Three partnership agreements with:
- the French company, Ipsen, in theranostics,
- Shanghai Institutes for Biological Sciences (SIBS), in industrial applications,
- Uppsala Clinical Research Center (UCR) in Sweden, to develop new biomarkers for cardiovascular diseases.

25 new products:
Including a CE-marked version of the VITEK® MS mass spectrometry solution for bacterial identification in microbiology laboratories. The Myla® middleware enables seamless integration between this new solution and the VITEK® platform, the world’s leading system for automated ID/AST.

Production base optimization with:
- the discontinuation of production at the Portland, OR (USA) plant,
- the extension of BacT/ALERT® bottle capacity at the Durham, NC (USA) plant,
- the opening of a new culture media production facility in Craponne (France).

Changes in corporate governance:
Since July 20th, Jean-Luc Belingard has served as Chairman and Chief Executive Officer of bioMérieux. Alexandre Mérieux, Directeur Général Délégué, was appointed Corporate Vice President of the Microbiology Unit.

2012 – 2015 ROADMAP
The Company is committed to undertaking four priority actions:
- Driving growth in its key markets: in clinical and industrial microbiology, in high medical value tests (VIDAS®) and in molecular biology extraction. It aims, in particular, to make China its third largest subsidiary.
- Anchoring its growth even more solidly in the launch of innovative solutions.
- Seizing every opportunity for targeted acquisitions and partnerships, while maintaining the Company’s solid financial structure. Opportunities will be selected for their strong strategic fit and potential for creating value.
- Strictly controlling operating costs, despite the launch of new systems, while undertaking the operating and organizational initiatives needed to meet its strategic objectives.
2,400 bioMérieux product references

25 new products in 2011 – over 150 in the last 5 years

Close to 65,000 instruments installed worldwide

4,900 new instruments in 2011
bioMérieux’s business is based on a balanced product portfolio and the exceptional world leadership position the Group enjoys in both clinical and industrial microbiology. In 2011, thanks to these solid fundamentals, bioMérieux realized organic sales growth of 4.1%, despite considerable deterioration in the international economic environment. In particular, it achieved an exceptional 8.2% increase in microbiology sales. After 2010, in which instrument sales were particularly high, its systems showed very dynamic growth of nearly 8% in 2011, thus paving the way for reagent sales in the months to come.

Furthermore, two strategic acquisitions served to solidify the Group’s position: in molecular diagnostics, with ARGENE, and in industrial microbiological control, with AES Laboratoire. This second acquisition strengthened bioMérieux’s global leadership position in industrial microbiology, making it number one in agri-food applications. The Group boosted its product offering across the board by launching 25 new products, in both clinical and industrial applications.
Microbiology lies at the heart of bioMérieux’s expertise. With nearly 50 years of experience in infectious diseases, a unique international scientific network and an ambitious innovation strategy, today we are the world leader in both clinical and industrial microbiology. Since 2006, our market share has increased from 30 to 42%. In 2011, our growth in microbiology is estimated to be double that of the sector.

We are committed to addressing major public healthcare challenges in infectious diseases across the globe. Combating the development of antimicrobial resistance and the emergence of new disease agents are two challenging areas where we focus our energies. As pioneers in microbiology, we strive to be a source of innovation and of medical value for our partners – biologists and clinicians. Our concept for the complete automation of microbiology labs (FMLA®) is a key part of this strategy.

Beyond simply providing results, we are determined to deliver high medical value information as quickly as possible: for patients and their physicians, to constantly improve the quality and effectiveness of treatment, and for biologists, to optimize the management of laboratory workflows. Our R&D programs are turned towards meeting these goals by combining our longstanding expertise with the power of new technologies.

Developing innovative products with high scientific value, accelerating time to results, and constantly improving automation and connectivity in microbiology laboratories and healthcare centers are bioMérieux’s priority objectives.

Alexandre Mérieux
Directeur Général Délégué
Corporate Vice President, Microbiology Unit
CLINICAL DIAGNOSTICS

In clinical diagnostics, which accounts for 82% of bioMérieux’s sales, growth was 4%.

Microbiology, the Company’s core business, saw exceptional growth of 8.2%. Today, it represents 52% of sales. With growth estimated to be double that of the market, bioMérieux has increased its market share in this business and confirmed its global leadership.

bioMérieux’s flagship products – VITEK® and BacT/ALERT® – performed well while the success of more recent solutions was confirmed: FMLA® for complete automation of microbiology labs, the VITEK® MS mass spectrometry-based bacterial identification system, and VITEK® 2 for antibiotic susceptibility testing.

Sales of immunoassays remained stable overall, but the VIDAS® range, which celebrated its 20th anniversary in 2011, continued to grow.

While the market is experiencing a consolidation phase in developed countries, causing sales of routine VIDAS tests to decrease, demand was steady for high medical value assays, such as B.R.A.H.M.S PCT and EBV. There was solid growth in emerging countries. In India, for example, VIDAS sales were up 30%, even though it is already a leading platform in this country.

ARGENE: A GROWTH ACCELERATOR FOR MOLECULAR DIAGNOSTICS

One of the highlights of 2011 was the acquisition of ARGENE, a French company specialized in molecular diagnostics. In the future, this acquisition will serve to enhance the test menu of the automated molecular biology platform currently under development (see page 22).

An immediate effect has been to strengthen bioMérieux’s product offering in molecular biology, in particular, specific testing for immunocompromised patients undergoing transplantation, a range of diagnostic tests that is currently growing very rapidly.

ARGENE is an international leader in the virological monitoring of transplant patients. Its products include quantitative tests for cytomegalovirus, Epstein-Barr virus and herpes simplex virus types 1 and 2. ARGENE’s products are recognized for their excellent quality.

This acquisition will generate significant synergies. Thanks to bioMérieux’s extensive global network, ARGENE’s products will be made available to a much broader customer base.

Combining ARGENE’s know-how in virology with bioMérieux’s expertise in microbiology should allow the Group to play a leading role in the monitoring of immunocompromised patients undergoing transplantation but also, more generally, in the field of healthcare-associated infections, sepsis and HIV infection.
CONTROLLING HAI: A TOP PRIORITY

FDA clearance for a new rapid molecular screening test in the U.S.

NucliSENS EasyQ® MRSA, an automated molecular test for Methicillin Resistant Staphylococcus aureus (MRSA), was granted clearance by the U.S. Food and Drug Administration (FDA).

The test delivers results in less than three hours, which makes it a precious aid for monitoring healthcare-associated infections (HAI). It allows physicians to react swiftly by isolating patients to limit the spread of bacteria, which is especially important given that MRSA are one of the leading causes of healthcare-associated infections.

Today bioMérieux provides the most comprehensive offering of MRSA solutions on the market: chromogenic media (chromID® MRSA) and molecular biology screening tests, VITEK® 2 for rapid identification and antibiotic susceptibility testing, Etest® for extended dilution MICs (minimum inhibitory concentration), and DiversiLab® for strain typing.

A new culture medium: chromID® C. difficile

In 2011, bioMérieux launched the first chromogenic culture medium for the isolation and identification of Clostridium difficile in just 24 hours. C. difficile is a bacterium responsible for healthcare-associated infections, which are highly transmissible. Some of these infections are very serious and can be associated with high mortality rates.

This new product bolsters bioMérieux’s offering in an area of key clinical importance.

FMLA® GAINS GROUND

In 2011, bioMérieux installed its 100th PREVI® Isola; a success that continued throughout the year.

PREVI Isola is an automated culture media streaking system designed to revolutionize front-end media processing tasks in microbiology laboratories. The 100th system was installed at the Grady Health System in Atlanta, Georgia, one of the largest public hospitals in the United States.

PREVI Isola is a critical component in bioMérieux’s complete range of Full Microbiology Laboratory Automation solutions and services. The Company focuses on building a close partnership with microbiologists to address their unique needs, from both a clinical and an economic viewpoint. In a context of restrictions in healthcare expenditures, FMLA offers benefits that are three-fold:

- accelerating time to results so that the best care for patients can be determined more rapidly,
- allowing laboratory staff to devote their time to tasks with high added value for clinicians and therefore for patients,
- optimizing laboratory productivity to handle increased test volumes and better manage surges in activity.

Laboratory managers today must handle an increasingly complex workflow with a smaller workforce and, in many cases, fewer skilled technicians. They are also faced with greater demand for quality assurance and traceability of samples and results.

The FMLA concept aims to improve connectivity and streamline the workflow in microbiology laboratories, from sample reception and distribution, microorganism identification and antimicrobial resistance analysis, to result management and interpretation. At the heart of bioMérieux’s microbiology strategy, a number of R&D programs are focused on FMLA, as illustrated by the Smart Incubator System project (see page 23).
Mass spectrometry: a successful launch

Pursuant to the collaboration agreement signed with Shimadzu in 2010, bioMérieux introduced the CE-marked version of the VITEK® MS mass spectrometry-based bacterial identification system for use in microbiology laboratories. This new identification solution is fully integrated with bioMérieux's VITEK® platform, the world’s leading system for identification and automated antibiotic susceptibility testing, via the Myla® middleware. Following an enthusiastic response in Europe, a request for clearance for use in routine bacterial identification will be filed with the U.S. Food and Drug Administration during 2012.

POINT-OF-CARE TESTING: THE bioNexia® RANGE IS LAUNCHED

Providing patients with access to diagnostic testing at the Point-of-Care, i.e., outside the bounds of the microbiology testing laboratory, particularly in doctors' offices, is an important focus of bioMérieux's efforts. This need can be met through rapid testing.

Because rapid tests are flexible and easy to use (taking less than 10 minutes to perform), they make it possible for patients to receive care and for doctors to prescribe the appropriate treatment very quickly.

In the field of rapid testing, bioMérieux is developing its bioNexia line, which is produced at the Shanghai plant in China. The first tests received CE mark approval in 2011. Five new products are now available:

- bioNexia® CRPplus for the semi-quantitative detection of C-reactive protein (CRP),
- bioNexia® FOBplus for the detection of blood in stools within the scope of colorectal cancer screening,
- bioNexia® BTA for the detection of a bladder cancer tumor marker,
- bioNexia® Influenza A+B for the detection and differentiation of Influenza A and B,
- bioNexia® Troponin I to detect myocardial infarction.

Other tests are expected to be CE-marked and should progressively enhance this range of manual immunoassays.

VIDAS*: 20 YEARS OF SUCCESS

Launched in 1990, the VIDAS range has met with unrivalled success. Today there are over 30,000 systems installed around the globe, including 26,000 systems in clinical labs, making it the world’s largest installed base for immunoassays in laboratories. bioMérieux has consistently enhanced and updated a broad menu featuring 110 parameters, of which 97 are for clinical applications.

Each second, somewhere in the world, three VIDAS tests are being performed – for clinical and industrial applications.

Many features have contributed to the VIDAS platform’s success: it is robust, simple to use, and offers a highly diversified menu. The system offers high medical value tests that are especially valuable in situations of emergency diagnostics.

VIDAS also offers solutions that are particularly well suited to emerging markets with a high demand for equipment.

Backed by the success of these first 20 years, the new generation VIDAS will be launched in late 2012.

3 new parameters in 2011:

- VIDAS® anti-TPO and VIDAS® anti-Tg: these two autoimmune disease diagnostic tests were added to round out the VIDAS® Thyroid panel.
- VIDAS® D-Dimer Exclusion II. This second generation test, used in emergency room settings, provides even more rapid results (20 minutes) to accurately exclude suspected deep vein thrombosis or pulmonary embolism.
INDUSTRIAL MICROBIOLOGICAL CONTROL

Representing 18% of bioMérieux’s sales, industrial applications contribute to upholding bioMérieux’s public health mission by preventing the risk of microbiological contamination during production in the agri-food, pharmaceutical and cosmetic industries.

2011 sales grew by 4.5% with sound market dynamics in the agri-food sector and the successful launch of six new products.

AES Laboratoire acquisition: strengthening bioMérieux’s leadership

Without a doubt, the acquisition of AES Laboratoire marked the high point of 2011. It strengthens bioMérieux’s world leadership in industrial microbiological control, making the Company number one in food applications, with approximately 20% of market share.

This acquisition gives bioMérieux access to complementary product lines and technologies (with cytometry in particular) as well as access to new markets, such as cosmetics and microbiological control for veterinary laboratories.

With the acquisition of AES Laboratoire, bioMérieux now has the most complete offering in food safety worldwide and can provide customers with a full range of microbiology laboratory solutions, from sample preparation to the identification of pathogenic microorganisms and the analysis of their virulence.

bioMérieux’s product offering has been strengthened with cytometry solutions for the detection of microorganisms, in particular ChemScan / Scan-RDI® (laser scanning cytometer). Today this is the only cytometer capable of providing microorganism counts with sensitivity down to a single cell, with no need for a culture phase. It provides nearly instantaneous results, enabling very rapid batch release without creating delays in the production cycle. This range of cytometers, already used in the pharmaceutical and cosmetics industries, offers considerable potential and developments are underway.

In addition to a broad range of manual and automated products that are highly complementary to those of bioMérieux, AES Laboratoire brings focused “niche” products, such as the EviSENSE range for metrology control (monitoring physical parameters such as temperature, pH and pressure) in agri-food and pharmaceutical production environments, as well as in hospitals.

With this major milestone, bioMérieux has reinforced its industrial microbiology expertise and become an international reference in this field.

BIOMÉRIEUX HONORED WITH THE BLACK PEARL AWARD

The International Association of Food Protection (IAFP) confers this distinction annually to one company that demonstrates excellence and commitment to improving food safety and food quality. Being selected for this award last year held particular meaning for bioMérieux because 2011 marked the celebration of IAFP’s 100th anniversary.

bioMérieux joins the ranks of other major companies from a range of sectors that have received this prestigious award in past years, including Kraft Foods, Dupont, Walt Disney, 3M and others.

By choosing bioMérieux, the jury recognized the quality of its employee training programs, a broad portfolio of innovative and officially certified products, and the Company’s commitment to ethical business practices and sustainable development, as well as the certification of its production sites.
**VIDAS® UP Salmonella (SPT): A much-awaited innovation in the agri-food sector**

Launched in 2011, VIDAS UP Salmonella (SPT) is a new and particularly innovative testing method. This new food safety solution utilizes recombinant bacteriophage proteins, which offer best-in-class specificity and sensitivity for the targeted capture and detection of *Salmonella* bacteria in food and environmental samples. The technology provides one-step sample preparation, which reduces laboratory hands-on time, and delivers results in less than 19 hours, as compared to traditional methods that require up to three days. It is a welcome addition to bioMérieux’s product line utilizing phage protein technology, which already includes a test for the detection of *Escherichia coli* O157 (including H7).

Much awaited by the market and able to take advantage of an installed base of 4,000 VIDAS® systems in microbiology control laboratories in the agri-food field, this new test was an immediate commercial success when it was launched.

The VIDAS menu of tests with phage protein technology should be expanded in 2012 with a test for the detection of *Listeria*.

**New culture media for the agri-food industry**

**chromID® Lmono: An “all-in-one” solution for *Listeria monocytogenes* testing**

*chromID® Lmono* is a new chromogenic medium that enables the rapid enumeration, detection and presumptive identification of *Listeria monocytogenes* in food products and production environment samples.

The *Listeria monocytogenes* enumeration takes just one day for a confirmed result whereas the ISO method requires 4 days.

**MWY: Culture medium for *Legionella* testing**

Commercialized in 2011, MWY is a selective culture medium for the detection and enumeration of *Legionella* in highly contaminated water such as that found in the cooling towers of air conditioning systems in public buildings, including hospitals.

**Enhancing our offering for the pharmaceutical industry**

BioMérieux has introduced new solutions specifically adapted to the needs of the pharmaceutical industry:

- **BioBall® Select**

  Following the commercialization of BioBall® Plant Isolate in 2010, the BioBall line has grown with the addition of a new service, BioBall Select, which can manufacture BioBall kits with any microbial strain selected from pharmacopoeia or regulatory texts. The products in the BioBall range contain a precise number of microorganisms in a water-soluble ball. BioBall kits make it possible to validate the performance of culture media used in industrial microbiological testing.

- **TSA 3™ and Count-Tact® 3P™ with Enhanced Neutralizers**

  Used for the environmental monitoring of pharmaceutical industry production zones, these culture media were designed specifically to neutralize the most aggressive disinfectants that may inhibit the growth of environmental microorganisms.

**New international recognition and awards**

In 2011, bioMérieux once again received international recognition and awards for its products. Reference institutions granted certifications acknowledging the excellence of the Company’s products, which represent an assurance of quality for customers.

These certifications and validations included:

- **AOAC RI (Research Institute)** for VIDAS® *Listeria monocytogenes Xpress*,
- **AOAC-OMA (Official Methods of Analysis)** for VIDAS® Easy Salmonella and VITEK® 2 Compact Gram Negative Card,
- **AFNOR** for VIDAS UP Salmonella and *chromID Lmono*,
- **FDA** for VIDAS® Staphylococcal enterotoxins,
- **MicroVal** (Dutch certification organization) for *chromID Lmono*,
- **Health Canada** for VIDAS® ECPT and VIDAS® LSX.
Over 1,000 employees worldwide at 16 research centers

- 6 joint research laboratories
- 50 partnerships with academic institutions and private research organizations worldwide
- 5 innovative platforms under development

Close to 11% of sales invested in R&D
Because *in vitro* diagnostics informs medical decisions, it is an essential link in the healthcare chain. Today the role played by diagnostics has changed considerably thanks to remarkable advances in medicine and the life sciences, coupled with the growth of new technologies. It is considered to be a powerful force in improving patient care and controlling healthcare costs. In its infancy, *in vitro* diagnostics made it possible to identify the causative agent of a disease or contamination. Since then, its applications have vastly expanded so that today it is possible to characterize the pathogenic agent and predict the progression of disease based on the patient’s profile. Diagnostics can also provide the basis for recommendations as to the most adapted therapy and analyze how a patient responds to treatment. In the agri-food and biopharmaceutical industries, microbiological control can prevent contamination, contributing to improving product quality and protecting consumers.

bioMérieux is determined to play a pioneering role in changing the face of diagnostics. To this end, the Company pursues an ambitious innovation strategy focused on two priorities:

- beyond providing increasingly reliable and effective tests and platforms, giving its partners – biologists, clinicians and industrial laboratories – more comprehensive, high medical value and/or predictive information, focused on the specific needs of the patient or consumer,

- optimizing the management of workflows and processes in clinical and control laboratories, with the dual objective of constantly reducing time to results and improving productivity.
bioMérieux devotes considerable resources to making these ambitions a reality:

- **Internal innovation programs**: capitalizing on nearly 50 years of experience and expertise in biology,
- **International alliances**: with academic institutions and private research organizations, the medical community and top life science institutions,
- **Acquisitions of new technologies**,
- **An active international scientific and technology watch** and close ties with Institut Mérieux’s research and medical departments,
- **Substantial financial investment**, exceeding the average percentage of sales invested by companies in the diagnostics industry.

In 2011, thanks to the efforts of its teams, bioMérieux brought 25 new products to market across all product lines. This mobilization contributed to consolidating and expanding its portfolio of products under development in microbiology, bioMérieux’s core expertise, as well as for new applications of especially promising technologies, such as sequencing and mass spectrometry. These R&D programs will fuel product launches that are promising for tomorrow’s healthcare.

### A NEW GENERATION OF VIDAS® IN 2012

The new generation of VIDAS is in the final stages of validation prior to its European launch in late 2012. Offering all the features that have made VIDAS so successful for the past 20 years, this new immunoassay platform will provide users with enhanced automation and traceability, new functions such as information technologies, and an increasingly ergonomic interface.

bioMérieux is also enhancing the VIDAS menu by developing new high medical value parameters in the field of cardiovascular diseases: VIDAS® Galectin-3 (to monitor chronic heart failure prognosis) and ultra sensitive VIDAS® CRP (to measure C-reactive protein, or hsCRP, for cardiovascular risk identification, stratification and prevention).

Vitamin D and hepatitis C tests are also being developed as new additions to a menu that already features 97 parameters.

### BRINGING DIAGNOSTICS TO THE PATIENT’S BEDSIDE

In time-critical situations such as those encountered in hospital emergency rooms, coronary units and intensive care units, being able to perform rapid diagnostic testing at the Point-of-Care should speed up and significantly improve patient outcomes.

To meet this challenge, in early 2010, bioMérieux and Royal Philips Electronics signed a joint development agreement for a rapid handheld diagnostic testing solution.

In 2011, this collaboration reached an important milestone with the successful integration of bioMérieux’s immunoassay technology and Philips’ new patented Magnotech biosensor platform into a disposable cartridge and handheld reader combination.

Both companies will now push forward with their development program. Philips will further develop its prototype handheld reader, while bioMérieux will continue assay development with initial applications for cardiovascular emergencies.
BIOMARKERS: MOVING TOWARDS MORE PERSONALIZED MEDICINE

bioMérieux continued to pursue programs to discover and validate new biomarkers for infectious and cardiovascular diseases and cancer. These tests make it possible for patients to receive more personalized care based on their genetic profile, so that doctors can prescribe treatments that are perfectly targeted and therefore more effective.

Partnership between Institut Mérieux and Institut Pasteur

Within the scope of a 2009 collaboration agreement between Institut Mérieux and Institut Pasteur, teams from bioMérieux and Institut Pasteur initiated four projects in 2011.

Their primary aim is to characterize patients’ immune response to infectious diseases by seeking to identify the biomarkers of microorganisms, their resistance to treatment, and the host response.

Taking the example of sepsis, the goal is to use new biomarkers to establish the prognostic evaluation for each patient, to obtain a stratification and determine the best treatment for each individual and, lastly, to detect possible organ failure extremely early to allow rapid intervention.

Collaboration with Swedish academic research

In the field of cardiovascular diseases, last December, bioMérieux entered into a strategic agreement with the Uppsala Clinical Research Center (UCR) in Sweden, for the development of new biomarkers.

This collaboration with a renowned academic institution will enhance bioMérieux’s pipeline of innovative laboratory and Point-of-Care diagnostic tests to improve care for patients with heart disease.

A new joint research laboratory with Hospices Civils de Lyon

In October 2011, bioMérieux and the Lyon Civil Hospitals inaugurated a new joint research laboratory located at Lyon-Sud hospital (France). The laboratory will focus on identifying new biomarkers for prostate cancer, with the aim of improving patient care throughout the different stages of the disease. The biomarkers should make it possible to confirm diagnosis when cancer is suspected, in addition to predicting the disease’s seriousness and progression in order to determine the most appropriate therapeutic strategy. Hospital clinicians and bioMérieux research teams work in synergy in the laboratory. Thanks to this privileged relationship with the medical community, bioMérieux researchers have access to patients and to biopsy samples, which will enable them to propose targeted solutions.

This exemplary collaboration is part of bioMérieux’s strategy to promote hospital/industry partnerships. To date, this approach has led to the creation of three similar laboratories worldwide – the joint laboratory established with the Edouard Herriot Hospital as well as similar collaborations with the Fudan University Cancer Center in Shanghai and the Immunology Institute in Singapore.
NEW STRIDES IN THERANOSTICS

Following the 2010 alliance between bioMérieux and GlaxoSmithKline (GSK) in the field of metastatic melanoma (skin cancer), a companion test developed by bioMérieux is expected to be launched in 2012 in Europe and submitted for FDA approval in the U.S. The new companion test will make it possible to identify patients who are eligible for treatment with GSK’s BRAF and/or MEK inhibitor compounds. This therapeutic strategy and preliminary clinical study results were discussed in an encouraging scientific presentation at the 2011 American Society of Clinical Oncology (ASCO) congress.

In early 2011, bioMérieux expanded its collaboration with Ipsen, which was initiated in 2008. This new partnership will focus on developing a shared, long-term approach in the field of personalized medicine and theranostics. The two companies will jointly identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of hormone-dependent cancers.

BIOHERANOSTICS NEWS

BioTheranostics continues to drive clinical and market adoption of its innovative biomarkers in the U.S. and several European countries. In the U.S., about 25% of oncologists have experienced bioTheranostics’ flagship product CancerTYPE ID, a leading molecular classifier to ascertain tumor tissue origin. Medicare, the U.S. public healthcare provider, issued a Coverage Policy of the product. Several successful clinical studies were published that further demonstrated CancerTYPE ID’s clinical utility.

Breast Cancer Index was launched in 2011. Scientists at bioTheranostics have illustrated that this novel biomarker differentiates itself from other breast cancer molecular tests with its distinct features of late recurrence prognosis and prediction of extended endocrine therapy benefit.

TWO IDEA LABS TO HELP IMAGINE TOMORROW’S DIAGNOSTICS

Since the inauguration of bioMérieux’s Future Lab in June 2011 at the Marcy l’Etoile (France) site, this avant-garde laboratory has welcomed over 1,000 visitors in one year. Given the Future Lab’s success, bioMérieux is currently building a similar structure in Saint Louis, Missouri (United States). These two idea labs are designed to allow customers to learn more about bioMérieux’s future products and services. These visits, which include presentations of new concepts in real-life situations, also provide an opportunity to collect feedback and suggestions from visitors. This exchange of ideas is very useful to validate and fine-tune projects under development, and even to imagine new ones. The two laboratories represent an excellent way to connect bioMérieux’s innovation teams with its customers and long-term market needs.

BROADER HORIZONS IN MOLECULAR DIAGNOSTICS WITH ARGENE

Following the collaboration agreement signed in 2010 with Biocartis, the project to develop a molecular diagnostics platform continued to gain ground, with significant resources invested at the Grenoble site. Today bioMérieux has an integrated prototype system and a menu of tests for healthcare-associated infections and sepsis is under development.

The acquisition of ARGENE generates important synergies and opens up new perspectives for this promising project. The Company is studying ways to adapt ARGENE’s tests (which are currently manual) to the automated platform under development, thereby providing new applications for immuno-compromised patients.
ADVANCED TECHNOLOGICAL RESEARCH

In a rapidly changing scientific and technical environment, identifying and integrating new technologies into R&D programs is a priority for bioMérieux. Coupled with the Company’s unique expertise in microbiology, this approach will make it possible to develop even faster and more effective diagnostic solutions with a direct impact on the quality of healthcare and industrial control.

bioMérieux focuses its technological research in five key areas:

1 – Laboratory automation
Because it is essential to accelerate time to results and optimize laboratory productivity, laboratory automation is a priority focus.

Beyond automating all the steps involved in diagnostics – from handling samples to interpreting results – bioMérieux strives to provide enhanced support for decision-making by biologists, real-time data transmission to clinicians, and remote access to data. Its goal is to provide actionable, value-added information. This is also important in industrial microbiological control, where rapid results are essential for manufacturing to run smoothly and for finished product batches to be released more quickly.

In 2011, bioMérieux’s teams focused on developing a new Smart Incubator System, whose first prototype will be presented in 2012. Thanks to imaging technology, the Smart Incubator System transforms the Petri dish into a digital object and offers new features: complete traceability, reading at scales undetectable to the human eye, and real-time remote access to data via the Myla® middleware.

2 – Mass spectrometry
VITEK® MS, for the identification of bacteria and yeast using MALDI-TOF mass spectrometry technology, came on stream in 2011. bioMérieux is pursuing research programs, in particular with the French Atomic Energy Commission (CEA), to prepare new generations of solutions based on mass spectrometry.

3 – Sequencing
As genome sequencing progresses at a rapid pace and its costs drop significantly, bioMérieux is studying the feasibility of a platform based on sequencing technology, with interesting potential applications in infectious disease diagnostics. This is a highly complex field where bioMérieux will benefit from partnerships such as the one signed in 2010 with the American company, Knome.

4 – Fast microbiology
bioMérieux continues to explore new technological and biological avenues to reduce the time required for culturing microorganisms, or even avoid this step altogether, which would make it possible to identify and potentially predict bacterial resistance in the space of a few hours. These new ultra rapid microbiology techniques would be especially valuable in emergency situations.

5 – Digital services
In a world where information technologies are impacting many economic sectors, bioMérieux can capitalize on the Company’s extensive knowledge of infectious diseases. Information about pathogens can be combined with information about diseases, treatments and epidemiology, as well as data specific to each individual patient (their medical history, clinical status and, ultimately, genome). By compiling all these data and making use of increased connectivity, it will be possible to develop new services with higher medical value.
87% of sales outside of France

40* subsidiaries

Present in over 160 countries

Double-digit growth in 11 countries

* Since March 2012.

27% of sales in emerging markets with strong growth potential
To fight pathogens that know no borders, bioMérieux has always had a strategy of international development. The Company has created an exceptional global network, with a balanced geographical footprint in both mature and emerging markets.

In a difficult global economic context, with deep differences from one region to another, the balance that characterizes bioMérieux’s geographic portfolio is today a valuable source of stability. bioMérieux’s performance in 2011 once again confirmed the effectiveness of this strategy.

Strong growth was observed in emerging markets, where the Group has operated for a number of years. It offset slower growth in Southern Europe, which has been significantly affected by budget restrictions that dampened sales. As a result, bioMérieux can look to the future with confidence.

Thanks to a broad and diverse product offering, bioMérieux is able to respond to very different needs from one country to another. In emerging markets, equipment is in high demand, while in more mature markets, high medical value tests are being increasingly used.
The Asia Pacific zone (16% of the consolidated total), achieved sales growth of over 12% in 2011.

In China, business expanded rapidly and sales growth reached 20%, although none of the tenders expected for 2011 were issued by Chinese authorities. bioMérieux has developed a Corporate hub there combining R&D, production and marketing activities. Reorganization of the distribution network in the Eastern region (Shanghai) and expansion into new territories (in the Beijing and Southern China regions) contributed significantly to these results. Furthermore, microbiology sales, with an excellent performance for the VITEK® 2 range, were boosted by the Ministry of Health’s new recommendations for a more rational use of antibiotics. Sales of the VIDAS® immunoassay system showed outstanding growth of 35%.

India recorded very brisk sales, up 28%, with genuine success stories such as that of the VIDAS range, which has made bioMérieux number two in immunoassays in India, with over 20% of market share.

In Japan, sales rose by 11%, bolstered by bioMérieux’s alliance with Sysmex and despite difficult market conditions. These results were due largely to the success of clinical microbiology solutions, especially VITEK® and BacT/ALERT®, as well as the VIDAS® B.R.A.H.M.S PCT test.

GROWING POPULARITY FOR VIDAS IN ASIA

In China, VIDAS sales grew by over 30% in 2011. The system’s flexibility, ease of use and comprehensive menu make it particularly well-adapted to the country’s changing healthcare landscape. Within the framework of China’s decentralization of healthcare, the VIDAS system was deployed in 120 small rural hospitals and Community Health Centers (CHC) in 2011. The automated system also meets the routine diagnostic testing needs of family planning centers, for couples expecting a child and taking advantage of the government’s recent, free pre-natal screening policy. Lastly, the significant development of Chinese hospitals has contributed to the success of high medical value biomarkers. The consumption of these tests is such that the VIDAS system is becoming increasingly popular in emergency laboratories in the different regions.

In India, VIDAS accounted for more than 40% of sales, with 30% growth in 2011. VIDAS is driving a trend for small and medium laboratories to adopt automated testing methods. Thus in Bansvara, a small district headquarter town in the State of Rajasthan, 5 small laboratories are catering to patients who may travel up to 150 km to be tested. All these laboratories were either using manual methods or outsourcing their analyses to big laboratories, sometimes outside the district. bioMérieux conducted a pilot with one customer and was able to demonstrate the advantages for a small laboratory to use mini VIDAS®. The care of patients from remote locations was improved thanks to results obtained more rapidly, the same day the sample was taken. The laboratory was able to process a greater volume of tests and to provide patients with higher quality results. After the pilot, in 2011, this initiative has grown to 180 customers.
In Latin America (9% of the consolidated total), sales grew by almost 16%, buoyed by the region’s economic expansion. Equipment and automated systems were in high demand and growth exceeded 10% in Brazil, Mexico, Argentina and Chile.

In clinical applications, the microbiology and VIDAS® immunoassay lines made significant gains, while sales of applications in industrial microbiology were vigorous in almost all countries.

BRAZIL: A LONGSTANDING PRESENCE IN LATIN AMERICA’S #1 MARKET

In Brazil, the region’s largest market, sales climbed rapidly by 18% in 2011.

Present in this country since 1973, bioMérieux has benefited from its strong economic development and increasing healthcare coverage among the population. Over the last three years, the proportion of Brazilians with private health insurance coverage has grown by five million people, who now have greater access to healthcare. This trend, combined with a move towards laboratory consolidation, has led to high demand for instruments. Growth has been dynamic in this country thanks, in particular, to the success of clinical microbiology applications and the VIDAS range.
In North America (22% of the consolidated total), sales rose 5.4%, which represents a satisfactory performance in light of this region’s uncertain economy. Hospitals maintained equipment investments, generating robust instrument sales for bioMérieux.

In clinical applications, results were positive for microbiology sales. Demand grew for the BacT/ALERT® range, led by strong instrument sales. VIDAS® once again confirmed its growth potential, in particular with the VIDAS® B.R.A.H.M.S PCT test. In addition, sales of FMLA® solutions rose, thanks in particular to the success of the PREVI® Isola automated pre-poured media streaker.

Lastly, significant interest for the VITEK® MS line, currently reserved for research applications, is encouraging. A request for clearance for the routine use of VITEK® MS for clinical diagnostic tests is expected to be filed with the FDA in 2012.

VIDAS B.R.A.H.M.S PCT: SUCCESS OF A HIGH MEDICAL VALUE TEST IN AMERICA

VIDAS B.R.A.H.M.S PCT is a success story in the U.S., with 120 new hospitals choosing it in 2011. This high medical value assay, introduced in 2007, is the focus of increasing attention from physicians, who appreciate its use as a valuable aid in the prognostic evaluation of sepsis.

In the first stages of an infection, measuring procalcitonin (PCT) – which is an early, specific marker of bacterial infection – makes it possible to rapidly distinguish between sepsis and a non-infectious inflammatory condition. This test helps to monitor and determine the prognosis of severe bacterial infections, as well as optimize antibiotic therapy. VIDAS B.R.A.H.M.S PCT provides clinicians with high medical value information in line with the specific needs of emergency departments.

bioMérieux has developed a number of awareness-raising and training initiatives about the clinical value of using this test. These initiatives, which target biologists and physicians in North America, have contributed to its resounding success.
Growth in these countries (53% of the consolidated total) slowed slightly, with contrasted performances from one region to the next.

Sales were robust in the Nordic countries, Germany and the United Kingdom, which offset difficulties encountered in Southern European countries, where governments were forced to implement austerity measures and healthcare budget restrictions. In addition to this challenging economic climate, laboratory consolidation gained momentum in France as a result of the medical biology reform act that took effect over the summer. In these mature markets, the effectiveness of bioMérieux’s product strategy was confirmed with solid sales for high medical value tests and robust growth in clinical microbiology, the Group’s field of expertise.

In the United Kingdom, clinical microbiology sales benefited from multi-year managed service contracts with hospitals, which should ensure substantial volume in the coming years.

Sales in Turkey climbed swiftly, with 18% growth. The Gulf countries, where bioMérieux achieved excellent results in microbiology, were also especially dynamic.

**A CENTER OF EXCELLENCE FOR MICROBIOLOGY IN GERMANY**

bioMérieux and Labor Berlin, which offers cutting-edge clinical diagnostic services in Germany, have combined their know-how to create a Center of Excellence for microbiology and enhanced laboratory automation. The center is located at Europe’s largest hospital laboratory, serving more than 8,000 in-house patients in Berlin and handling over 23 million patient analyses per year.

Through their agreement, the partners aim to improve the efficiency and quality of care by taking a more personalized approach to medicine, and determining, as quickly as possible, the therapy that is best suited to each individual patient. Labor Berlin and bioMérieux are working together to integrate the newest diagnostic and information technologies available into the laboratory. This state-of-the-art laboratory will also make it possible to test the solutions in the FMLA® range and provide clinical performance evaluations of these new diagnostic solutions.

**MICROBIOLOGY GAINS GROUND IN THE GULF COUNTRIES**

In Saudi Arabia, bioMérieux has become the leading supplier to microbiology laboratories in five major hospitals, thanks in particular to the VITEK® and BacT/ALERT® systems. Three new hospitals in Qatar and Kuwait were also won over by bioMérieux’s Full Microbiology Laboratory Automation solutions. These results were made possible thanks to the Company’s expertise and comprehensive microbiology offering as well as the remarkable efforts by the network of distributors in this region of the world.
3 corporate hubs for R&D/production/commercial activities in France, the U.S. and China

21 specialized industrial sites in 9 countries

Nearly 3,000 people employed in biomanufacturing operations

€74 million invested in 2011 to improve the Group’s bioindustrial capacities and information systems

More than 650 million tests and 8,000 systems produced in 2011
bioMérieux’s bioindustrial network is a strategic asset for its development. For many years, the Company has been investing in production capacities and organizing a solid international network. Thanks to the strength of this network, bioMérieux is able to ensure that products meeting the most stringent international quality standards are delivered to customers across the globe.

In an uncertain economic environment and to meet the demands of emerging markets, the flexibility of bioMérieux’s production teams enabled the Company to successfully manage significant fluctuations in volume during the year.

bioMérieux also continued to streamline its culture media production potential in the United States while investing in various countries to enhance bioindustrial capacities and improve productivity for different product lines.
BUILDING NEW CAPACITY FOR NEW PRODUCTS

bioMérieux pursued its bioindustrial investment policy to keep pace with the development of its business.

Among the milestones achieved in 2011:
■ Expansion of the new generation BacT/ALERT® blood-culture bottle manufacturing capacity at the Durham, North Carolina site (United States). This new production line, which represented a substantial investment ($27 million), will increase and strengthen existing BacT/ALERT bottle production capacity;
■ Start-up of a new production unit in Craponne (France) dedicated exclusively to the manufacture of culture media for the pharmaceutical industry. This unit, which represents a €6 million investment, will produce Count Tact® media (environmental monitoring) as well as LockSure® Petri dishes (with secure locking technology) to meet growing demand.

STREAMLINING THE CULTURE MEDIA PRODUCTION NETWORK

The North American site in Portland, Oregon was closed in 2011. Routine culture media for clinical applications were phased out, while the production of other products was transferred to Group facilities in Lombard, Illinois (United States) and La Balme (France). The aim of this restructuring is to enhance efficiency and productivity by streamlining the culture media production network. bioMérieux intends to pursue this strategy in 2012 to offer customers one of the most extensive lines of culture media on the market at competitive prices.

Parallel to restructuring the culture media business in the United States, investments were made in France, Spain, Brazil and China to increase culture media production capacities.
DEMONSTRATING FLEXIBILITY AND RESPONSIVENESS

In response to variable demand in 2011, driven in particular by a very dynamic month of December and strong instrument sales in emerging countries, bioMérieux needed to adjust to fluctuating production volumes. The Group’s bioindustrial network once again demonstrated a high degree of flexibility and was able to satisfy customers’ needs.

Across all sites and product lines, the organization responded with teams working night shifts to meet peaks in demand. Thanks to their remarkable performance, instrument manufacturing sites were able to ensure production levels that at times rose to 35 to 45% above initial forecasts. At the same time, they continued to meet the same high standards for both employee safety and product quality.

bioMérieux continues to develop and invest in its industrial organizations, processes and assets to meet future customer needs in this dynamic business environment.

INTEGRATING ARGENE AND AES LABORATOIRE SITES: A SUCCESSFUL START

Following the acquisition of these two companies in 2011, teams from ARGENE, AES Laboratoire and bioMérieux successfully initiated their integration process with the goal of developing bioindustrial synergies, exchanging good manufacturing practices, optimizing processes, and transferring activities when necessary. With these two newly-acquired companies, bioMérieux has four new production sites that comply with the most stringent quality standards: three sites for industrial microbiological control activities and one site for molecular biology tests.

This momentum will continue over the coming months as the new sites are fully integrated into the Group’s international production network.

NEW INTERNATIONAL QUALITY CERTIFICATIONS

- The Saint Louis, Missouri (United States) site received a number of government agency inspections, including the FDA, and successfully met expectations.
- GMP certification delivered by the SFDA (Chinese Food and Drug Administration) for the bioMérieux/Kehua joint venture manufacturing site in Shanghai.
- ATCC and LNE-GMED audit passed with success at the La Balme (France) site following the transfer of the LyfoCult® and LyfoCult® Plus lines, formerly manufactured in Portland, Oregon (United States).
- Audit by the World Health Organization passed with success at the Grenoble (France) site for the approval of the molecular biology test NucliSENS® HIV-1 2.0.
- First ISO 17025 certification for the quality control laboratory at the Craponne (France) site, so that there is no need for customers – particularly in the agri-food industry – to control bioMérieux culture media upon reception.
300 new jobs created in 2011 across all sites

33 hours training per employee on average each year

A corporate sponsorship budget of nearly €19 million supporting 10 years of initiatives

BIOMÉRIEUX GOES GREEN: 4 years of progress

* Since March 2012.
As a public health leader with a global presence, bioMérieux places patients and, more broadly, people, at the heart of its activities. Convinced of its corporate social responsibility, bioMérieux takes a long-term perspective to upholding its medical, scientific, social and environmental commitments.

In conducting its business, bioMérieux never loses sight of this responsibility – by developing and commercializing products that enable patients to benefit from clinical breakthroughs, by improving access to quality diagnostics for disadvantaged patients, by promoting employees’ personal and professional development, and by adopting a bioindustrial policy that respects the environment.

At the international level, the Company renewed its commitment to the Global Compact’s principles. The United Nations introduced this initiative in 1999, asking companies to embrace ten key principles in the areas of human rights, labor and the environment.

In 2011, bioMérieux stepped up efforts in the global fight against bacterial resistance to antibiotics, which represents a major public health threat. The Company actively supported the Mérieux Foundations in their work to combat infectious diseases that affect developing countries.

Making the quality of human relations a priority, bioMérieux implemented new tools to promote working relations within the Group and to strengthen individual and collective performance.

Finally, bioMérieux continued to implement the BIOMÉRIEUX GOES GREEN program across all sites worldwide, with the aim of preserving the environment.
**FIGHTING ANTIMICROBIAL RESISTANCE**

The development of bacterial resistance to antibiotics and hospital-acquired infections, as well as the emergence of new disease agents against which available antibiotics are ineffective, represent major public health concerns today. The emergence of pan-resistant NDM-1 bacteria and multidrug-resistant *E. coli* infections in Europe clearly illustrate the seriousness of this threat.

Diagnostic tests play an essential role in curbing the spread of multidrug resistant bacteria. They help clinicians decide whether an antibiotic will cure an infection and choose the most appropriate treatment. In addition, these tests are a precious tool for healthcare authorities in epidemiological surveillance and prevention programs.

*bioMérieux’s longstanding expertise in infectious diseases is a valuable asset in the fight against antimicrobial resistance.* Beyond the Group’s offering of products and dedicated services, *bioMérieux* is involved in initiatives to increase awareness and mobilize efforts on behalf of this cause.

**World HAI Forum**

At the initiative of *bioMérieux*, over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, coming from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections. At the end of high-level debates and presentations, the participants called upon national and international health authorities, the medical and veterinary communities, industry leaders, and the general public to take global action to combat the emergence and spread of bacteria that are resistant to antibiotics.

In line with calls to action and proposals made by major national and international organizations (WHO, ECDC, IDSA, CDC, etc.), the Forum’s participants identified priority action areas to fight the spread of bacterial resistance and recommended 12 concrete actions to effectively address this serious problem. Their recommendations concern different areas, such as epidemiological surveillance, effective training for healthcare professionals and veterinarians, educating the public, stronger regulations and the development of new rapid diagnostic tests.

**European Antibiotic Awareness Day**

*bioMérieux* actively supported the European Antibiotic Awareness Day, organized by the European Centre for Disease Prevention and Control (ECDC) in November 2011.

The goal of this awareness-building initiative is to invite the public, clinicians and the pharmaceutical industry to use antibiotics responsibly.

*bioMérieux* subsidiaries throughout the world provided educational tools for healthcare professionals to help increase public awareness about this serious issue and the critical role played by diagnostics.
MAKING STRIDES IN INFECTIOUS DISEASE RESEARCH: THE T.R.I. IN LYON

As a major player in the field of infectious diseases, bioMérieux is committed to promoting the development of research in this area in France. Through the Institut Mérieux, the Company supported a project to create a Technological Research Institute (T.R.I.) in Infectious Diseases. This initiative was selected in 2011 within the framework of the French government’s “Investments for the Future” program.

Developed by Lyonbiopole and Institut Pasteur, the Technological Research Institute is intended to become an internationally renowned campus for research in infectious diseases. Teams will work in over 40,000 square meters (about 430,000 square feet) devoted to innovation at a main site in Lyon Gerland, as well as at the Institut Pasteur in Paris. This project represents an investment of €145 million for the first three years.

Based on a unique public/private partnership model, the T.R.I. in Infectious Diseases brings together the founding companies and major players in industry (Sanofi, Institut Mérieux, Danone Research) with French research organizations (INSERM, CNRS, CEA) and a non-profit association of over 50 small- and medium-sized companies, as well as representatives of academia and the hospital community.

The ambitious challenge set by this T.R.I. and its partners is to better understand infectious diseases in order to provide comprehensive and personalized disease management for patients, with a focus on three research programs:

- “New therapies and vaccines”
- “Intestinal microbiota: an indicator and a healthcare product”
- “Towards real-time diagnosis”, a topic of particular interest for bioMérieux.

IMPROVING ACCESS TO QUALITY DIAGNOSTICS FOR ALL PATIENTS

True to its mission to improve public health worldwide, bioMérieux supports the actions of the Fondation Mérieux and the Fondation Christophe et Rodolphe Mérieux, which are dedicated to working locally to fight infectious diseases in disadvantaged regions of the globe.

This foundation, which celebrated its tenth anniversary in 2011, has carried out a number of initiatives in developing countries. Since 2001, bioMérieux has provided close to €10 million to support the Fondation Christophe et Rodolphe Mérieux.

10 YEARS OF INITIATIVES IN THE FIELD

Thanks to the support of its partners, the Fondation Christophe et Rodolphe Mérieux:

- is present in 8 countries: Haiti, Mali, Madagascar, Lebanon, Tajikistan, China, Laos and Cambodia,
- has created 7 reference laboratories, the Rodolphe Mérieux Laboratories, which are dedicated to training biologists, diagnosing diseases specific to these countries, and supporting applied research,
- is working on 2 new projects for laboratories in Bangladesh and Brazil,
- has awarded 5 Christophe Mérieux prizes to scientists conducting research locally in the fields of malaria, AIDS and cysticercosis – in Africa, the Caribbean, Asia and Latin America.
Rebuilding Haiti

In 2011, bioMérieux designed, equipped and delivered an automated clinical biology laboratory to the Port-au-Prince Hospital, which was completely destroyed by the 2010 earthquake.

This initiative is part of a broader action plan initiated by the Institut Méérieux and its companies in collaboration with the Méérieux Foundations. Among their achievements:

- Rebuilding and expanding the clinical biology laboratory at the GHESKIO* Center, which was damaged during the earthquake. Today 70 Haitians work in the laboratory, which is in charge of diagnosing tuberculosis and cholera for the entire country;
- Setting up a training program for laboratory technicians in partnership with the ESTBB (Catholic University of Lyon). The first class of technicians began their courses in 2011;
- Increasing significantly the number of microcredit loans to seropositive women receiving care at the GHESKIO Center;
- Building wooden homes for children from two orphanages.

In addition, the Christophe Méérieux prize awarded by the Fondation Christophe et Rodolphe Méérieux to Professor Jean William Pape in 2010 enabled him to enlarge the GHESKIO Center in Port-au-Prince. As of 2011, the center’s capacity has grown and it can provide care for more patients.

* GHESKIO: the Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections.

A CORPORATE COMMITMENT

AN INITIATIVE FOR CHILDREN IN ARGENTINA

bioMérieux Argentina participated in the ALMA Hospital Train for Children (Tren-Hospital para Chicos), a program designed to improve the health of children in remote locations with limited access to healthcare. Organized by the Fundación ALMA, the train travels to resource-challenged villages in the Northern Argentinean provinces. bioMérieux donated diagnostics for Chagas testing and laboratory equipment. The subsidiary’s employees also collected supplies to ensure the children’s good hygiene. 1,500 children in five villages benefited from screening for diseases as well as educational programs on food safety and hygiene.
UNDERSTANDING AND ENCOURAGING EMPLOYEE ENGAGEMENT

Aware that its teams and employees are a precious asset, bioMérieux sought to better understand their engagement so that the Company can develop while enabling each individual’s professional fulfillment.

In late 2011, a survey was conducted among the Group’s 7,000 employees. This initiative was well received, with a response rate of 85%. An analysis of the survey findings will provide the basis for action plans, team by team, in a dynamic approach designed to achieve long-term progress.

This in-house barometer is particularly valuable for the Group’s human resources policy. It is the first in a series of actions that will make it possible to take stock of employee feedback on a regular basis to improve both individual and global performance.

PRESERVING THE ENVIRONMENT

Preserving the environment and the Planet’s resources to promote better health among the different communities with which the Company interacts, as well as for future generations, is a priority for bioMérieux. As a public health player, bioMérieux is determined to take the environment into account in all its biindustrial activities and to include it in all aspects of the Company’s day-to-day business.

For this reason, the BIOMÉRIEUX GOES GREEN environmental action plan was introduced in 2008. Since then it has continued to gain ground each year thanks to strong support from the Group’s employees, who have embraced this initiative.

A Sustainable Development Committee, made up of representatives of all the Company’s functions, oversees the initiative. A network of more than 40 “Green Champions” worldwide is in charge of implementing the action plans. At each site and within each subsidiary, the Champions help drive the strategy and offer recommendations. In addition, the training programs provided by bioMérieux University include raising awareness about the Group’s environmental approach.

bioMérieux’s commitment is focused on five priority areas: energy, water, paper, waste and emissions, with the goal of reducing the environmental impact of the Group’s activities.
A significant reduction in water consumption

Water is used by bioMérieux to manufacture its products, in refrigeration facilities, and for cooling during production processes. The Company seeks to use closed-loop cooling systems and is vigorously pursuing a policy to replace first-generation once-through cooling systems. Similarly, new buildings are designed to recover rainwater that can be used for irrigation. In 2011, a program to monitor water consumption at the Tres Cantos (Spain) site contributed to reducing annual water use there by over 30%.

Since the launch of BIOMÉRIEUX GOES GREEN in 2008, water consumption across the Group has been reduced by more than 15%*.

* Ratio of consumption as compared with bioMérieux sales, excluding ARGENE and AES Laboratoire.

Limiting paper consumption

All bioMérieux sites and subsidiaries organize initiatives to reduce paper consumption and promote the use of recycled paper.

A new printing system, which uses less paper, was introduced in France in 2010. It was then adopted in several European, South American, Chinese and Australian subsidiaries in 2011 and is gradually being implemented throughout the Company.

In North America, paper consumption has been reduced by 30% since 2008, and in France by over 40%.

For product package inserts and instructions for use, bioMérieux has continued the conversion to electronic files available online. Following a pilot phase with the TEMPO® system, the inserts for several product lines are now provided online. bioMérieux Colombia has adopted this approach, which should be rolled out in all countries where the electronic format is accepted by the regulatory authorities. The entire Company saved an estimated 80 tons of paper in 2011, thanks to the implementation of electronic instructions for use.

Promoting greater energy efficiency

bioMérieux has implemented a program to optimize and reduce energy consumption. Prior to the design, construction and renovation of buildings, simulations assess the energy efficiency of lighting, heating and ventilation systems. The Company seeks, encourages and is progressively adopting low energy consumption solutions. In addition, an energy efficiency study is carried out when it comes time to replace equipment. More broadly, in 2011, bioMérieux implemented a procedure including a prerequisite review of the environmental, health and safety aspects of all investment projects.

The combined energy measures put in place since 2008 have led to a 14%* drop in energy consumption.

* Ratio of consumption as compared with bioMérieux sales, excluding ARGENE and AES Laboratoire.
Optimizing waste management

bioMérieux strives to optimize waste management, focusing in particular on reducing the overall amount of waste while increasing recycling and energy recovery. For the entire Group, the portion of recycled or incinerated waste with energy recovery exceeded 60%* in 2011. At the Durham, North Carolina site in the U.S., for example, audits of recycling practices were performed periodically: the rate of recycled waste and energy recovery (through recycling or composting) reached 80% in 2011.

A composting system for food waste is in place at the major U.S. sites. It was extended to the La Balme (France) site in 2011, in partnership with the cafeteria and grounds maintenance services. This initiative was supported by ADEME** for its innovative features, organic waste transformation and use of resulting compost in situ.

Reducing emissions

bioMérieux is committed to reducing greenhouse gas emissions, and four of its French sites have undertaken calculations of their carbon footprint.

The Company actively seeks to reduce travel-related emissions. Whenever possible, new alternative means of communication are provided. bioMérieux also encourages employees to carpool and use public transportation.

In Colombia, for example, employees have increased carpooling in response to measures by the city of Bogota to reduce traffic jams. In France, since 2011, new parking lots at the Craponne site are equipped with electric vehicle charging stations.

To reduce emissions generated when providing technical assistance to customers using bioMérieux instruments, the Company is studying alternatives that will make it possible to cut back on travel by engineers, thereby limiting the Company’s carbon footprint.

The VILINK® remote solution offers one example of a success story. This solution provides users of VITEK® 2 with access to customer service personnel to resolve issues and provide preventive maintenance remotely via a highly secure, rapid connection. By late 2011, more than 1,100 bioMérieux instruments installed in customers’ laboratories had been equipped with this option.

* Excluding ARGENE and AES Laboratoire.
** French Environment and Energy Management Agency.

SOLID PROGRESS IN 2011*

- Water consumption: reduced by over 15% (in m³/€m, as compared with sales)
- Paper use: reduced by 30% in North America and over 40% in France (in absolute value)
- Energy consumption: reduced by 14% (MWh/€m, as compared with sales)
- Waste-to-energy & recycled waste: > 60%
- ISO 14001 environmental certification renewed for bioMérieux Switzerland and obtained by two new subsidiaries, bioMérieux Brazil and bioMérieux UK

* Evolution since 2008, excluding ARGENE and AES Laboratoire – estimations and internal data covering 90% of the Group’s subsidiaries.
MANAGEMENT COMMITTEE

The Management Committee, chaired by Jean-Luc Belingard, meets monthly.

In 2011 it is comprised of:

8 Jean-Luc Belingard, Chairman and CEO
9 Michel Baguenault, Corporate Vice President, Human Resources
3 Thierry Bernard, Corporate Vice President, Global Commercial Operations
4 Richard Ding, Corporate Vice President, Business Development and Chief Executive Officer, bioTheranostics, Inc.
6 Jean-Marc Durano, Corporate Vice President, Industrial Microbiology Unit
5 Steve Harbin, Corporate Vice President, Manufacturing and Supply Operations, Quality Management, Regulatory Affairs & Information Systems
1 François Lacoste, Corporate Vice President, Immunoassay Unit
10 Marc Mackowiak, Chief Executive Officer, bioMérieux, Inc.
2 Alexandre Mérieux, Corporate Vice President, Microbiology Unit
11 Alain Pluquet, Corporate Vice President, Innovation and Systems Unit
7 Henri Thomasson, Chief Financial and Legal Officer
BOARD OF DIRECTORS
The Board, chaired by Jean-Luc Belingard, met 5 times in 2011. It is comprised of 9 members:
- Jean-Luc Belingard - Chairman
- Alain Mérieux
- Alexandre Mérieux - Directeur Général Délégué
- Michel Angé
- Philippe Archinard
- Christian Bréchot
- Groupe Industriel Marcel Dassault represented by Benoît Habert
- Georges Hibon
- Michele Palladino
- and of Harold Boël - Censor.

COMMITTEES OF THE BOARD OF DIRECTORS
The Audit Committee met 7 times in 2011. It is comprised of Michel Angé, its chairman, Benoît Habert and Georges Hibon.

The Human Resources Committee: Nominations and Compensation met twice in 2011. It is comprised of Alain Mérieux, its chairman, Michele Palladino and Michel Angé.

STRATEGY COMMITTEE
This committee is comprised of Alain Mérieux, its chairman, Jean-Luc Belingard and Alexandre Mérieux.
关键数字

销售收入

销售收入（以百万欧元计）
尽管在困难的经济环境和背景下，销售收入仍以6.5%的复合年增长率（不考虑汇率变动）和4.1%的有机增长率增长。

销售渠道

销售渠道

全球平衡的地理分布限制了政府紧缩措施的影响，特别是在南欧国家，并使公司能够把握市场机遇，特别是新兴市场。新兴7注册了接近16%的有机增长，排除了因非战略性产品在印度而结束的分销合同的影响。

销售渠道

销售渠道

三个主要业务驱动力注册了坚实的有机增长：8.2%的微生物学增长率，接近4%的VIDAS®范围，和4.5%的工业应用。

运营前非经常项目收入

运营前非经常项目收入

博美瑞尔表现了坚实的运营表现，运营前非经常项目收入达到了18%的销售额。

净利润

净利润

净利润为1.61亿欧元，代表了11.2%的销售额。
R&D EXPENSES (in millions of euros)

In the context of launching five innovative platforms in 2012 and 2013, R&D expenses represented close to 11% of Company sales. They stood at 152 million euros, a 3% increase at constant exchange rates.

CAPITAL EXPENDITURE (in millions of euros)

Industrial capital expenditure was mainly for production capacity improvements and extensions, building development work and the global ERP project. After two particularly high years, the total amount invested over the year represented 7.5% of sales.

FREE CASH FLOW* (in millions of euros)

bioMérieux generated 118 million euros in free cash flow, a significant increase over previous years.

* Free cash flow before acquisitions and dividends.

FINANCIAL STRUCTURE (in millions of euros)

Net debt stood at 131 million euros, representing 12% of equity. This leaves significant financial latitude for the Group to pursue its strategic ambitions.

TOTAL WORKFORCE* AS AT DECEMBER 31ST

The Company had 7,014 employees at the end of 2011, including 451 from AES Laboratoire and ARGENE. This increase also reflects the reinforcement of production and sales & marketing teams.

* In full-time equivalents.
### CONSOLIDATED INCOME STATEMENT

<table>
<thead>
<tr>
<th></th>
<th>Jan. 11 - Dec. 11 12 months</th>
<th>Jan. 10 - Dec. 10 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Sales</strong></td>
<td>1,427.2</td>
<td>1,357.0</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>-666.1</td>
<td>-634.9</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>761.1</td>
<td>722.1</td>
</tr>
<tr>
<td><strong>Other operating income</strong></td>
<td>20.7</td>
<td>22.7</td>
</tr>
<tr>
<td><strong>Selling and marketing expenses</strong></td>
<td>-264.5</td>
<td>-238.8</td>
</tr>
<tr>
<td><strong>General and administrative expenses</strong></td>
<td>-107.6</td>
<td>-103.2</td>
</tr>
<tr>
<td><strong>Research and development expenses</strong></td>
<td>-152.1</td>
<td>-149.2</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>-524.2</td>
<td>-491.2</td>
</tr>
<tr>
<td><strong>Operating income before non-recurring items</strong></td>
<td>257.6</td>
<td>253.6</td>
</tr>
<tr>
<td><strong>Other non-recurring income (expenses)</strong></td>
<td>-12.2</td>
<td>-9.6</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>245.4</td>
<td>244.0</td>
</tr>
<tr>
<td><strong>Cost of net financial debt</strong></td>
<td>-4.4</td>
<td>-3.2</td>
</tr>
<tr>
<td><strong>Other financial items</strong></td>
<td>-3.3</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Income tax</strong></td>
<td>-77.3</td>
<td>-81.4</td>
</tr>
<tr>
<td><strong>Investments in associates</strong></td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Net income of consolidated companies</strong></td>
<td>160.5</td>
<td>160.0</td>
</tr>
<tr>
<td><strong>Attributable to the minority interests</strong></td>
<td>2.3</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Attributable to the parent company</strong></td>
<td>158.2</td>
<td>158.7</td>
</tr>
<tr>
<td><strong>Basic net income per share</strong></td>
<td>4.01 €</td>
<td>4.03 €</td>
</tr>
<tr>
<td><strong>Diluted net income per share</strong></td>
<td>4.01 €</td>
<td>4.03 €</td>
</tr>
</tbody>
</table>
# CONSOLIDATED BALANCE SHEET

<table>
<thead>
<tr>
<th>ASSETS in millions of euros</th>
<th>Net 12/31/2011</th>
<th>Net 12/31/2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible assets</td>
<td>184.4</td>
<td>122.7</td>
</tr>
<tr>
<td>Goodwill</td>
<td>334.3</td>
<td>188.7</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>367.0</td>
<td>340.1</td>
</tr>
<tr>
<td>Financial assets</td>
<td>26.9</td>
<td>26.6</td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>31.5</td>
<td>28.0</td>
</tr>
<tr>
<td>Deferred tax assets</td>
<td>28.2</td>
<td>24.9</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>972.2</strong></td>
<td><strong>731.2</strong></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories and work in progress</td>
<td>217.1</td>
<td>179.5</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>447.1</td>
<td>403.0</td>
</tr>
<tr>
<td>Other operating receivables</td>
<td>50.4</td>
<td>48.0</td>
</tr>
<tr>
<td>Tax receivable</td>
<td>19.6</td>
<td>2.9</td>
</tr>
<tr>
<td>Non-operating receivables</td>
<td>1.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>42.7</td>
<td>71.4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>777.9</strong></td>
<td><strong>705.5</strong></td>
</tr>
<tr>
<td>Assets held for sale</td>
<td>12.0</td>
<td>12.0</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>1,762.2</strong></td>
<td><strong>1,448.7</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND SHAREHOLDERS’ EQUITY</th>
<th>12/31/2011</th>
<th>12/31/2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SHAREHOLDERS’ EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Share capital</td>
<td>12.0</td>
<td>12.0</td>
</tr>
<tr>
<td>Additional paid-in capital &amp; Reserves</td>
<td>925.1</td>
<td>800.9</td>
</tr>
<tr>
<td>Net income for the year</td>
<td>158.2</td>
<td>158.8</td>
</tr>
<tr>
<td><strong>Total equity before minority interests</strong></td>
<td><strong>1,095.4</strong></td>
<td><strong>971.7</strong></td>
</tr>
<tr>
<td>Minority interests</td>
<td>8.0</td>
<td>4.4</td>
</tr>
<tr>
<td><strong>Total shareholders’ equity</strong></td>
<td><strong>1,103.4</strong></td>
<td><strong>976.1</strong></td>
</tr>
<tr>
<td><strong>NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net financial debt - long-term</td>
<td>12.6</td>
<td>7.5</td>
</tr>
<tr>
<td>Deferred tax liabilities</td>
<td>41.2</td>
<td>24.8</td>
</tr>
<tr>
<td>Provisions</td>
<td>33.2</td>
<td>31.6</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>87.0</strong></td>
<td><strong>63.9</strong></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net financial debt - short-term</td>
<td>161.3</td>
<td>39.6</td>
</tr>
<tr>
<td>Provisions</td>
<td>14.0</td>
<td>14.4</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>142.6</td>
<td>128.9</td>
</tr>
<tr>
<td>Other operating liabilities</td>
<td>198.9</td>
<td>185.2</td>
</tr>
<tr>
<td>Tax liabilities</td>
<td>27.3</td>
<td>15.6</td>
</tr>
<tr>
<td>Non-operating liabilities</td>
<td>27.7</td>
<td>25.1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>571.8</strong></td>
<td><strong>408.8</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and shareholders’ equity</strong></td>
<td><strong>1,762.2</strong></td>
<td><strong>1,448.7</strong></td>
</tr>
</tbody>
</table>

FINANCIAL RESULTS
### CONSOLIDATED CASH FLOW STATEMENT

<table>
<thead>
<tr>
<th></th>
<th>Jan. 11 - Dec. 11 12 months</th>
<th>Jan. 10 - Dec. 10 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income of consolidated companies</td>
<td>160.5</td>
<td>160.0</td>
</tr>
<tr>
<td>Net depreciation and provisions, and others</td>
<td>88.7</td>
<td>88.3</td>
</tr>
<tr>
<td>(Increase) / Decrease in fair value of derivatives</td>
<td>0.3</td>
<td>1.2</td>
</tr>
<tr>
<td>Net realized capital gains (losses)</td>
<td>0.2</td>
<td>-0.4</td>
</tr>
<tr>
<td><strong>Cash flow from operating activities</strong></td>
<td><strong>249.7</strong></td>
<td><strong>249.1</strong></td>
</tr>
<tr>
<td>Cost of net financial debt</td>
<td>4.4</td>
<td>3.2</td>
</tr>
<tr>
<td>Current income tax expense</td>
<td>78.7</td>
<td>76.3</td>
</tr>
<tr>
<td><strong>Cash flow from operating activities before cost of net financial debt and income tax</strong></td>
<td><strong>332.8</strong></td>
<td><strong>328.6</strong></td>
</tr>
<tr>
<td>Increase in inventories</td>
<td>-18.5</td>
<td>-13.1</td>
</tr>
<tr>
<td>Increase requirements in accounts receivable</td>
<td>-29.2</td>
<td>-37.5</td>
</tr>
<tr>
<td>Increase (Decrease) in accounts payable and other operating working capital</td>
<td>-2.0</td>
<td>8.7</td>
</tr>
<tr>
<td><strong>Decrease / (Increase) in operating working capital</strong></td>
<td><strong>-49.7</strong></td>
<td><strong>-41.9</strong></td>
</tr>
<tr>
<td>Income tax paid</td>
<td>-65.7</td>
<td>-74.5</td>
</tr>
<tr>
<td>Other</td>
<td>1.7</td>
<td>-14.4</td>
</tr>
<tr>
<td>(Increase) / Decrease in non-current assets</td>
<td>-2.5</td>
<td>1.2</td>
</tr>
<tr>
<td><strong>Decrease / (Increase) in working capital requirements</strong></td>
<td><strong>-116.2</strong></td>
<td><strong>-129.6</strong></td>
</tr>
<tr>
<td>Net cash flow from operations</td>
<td>216.6</td>
<td>199.0</td>
</tr>
<tr>
<td>Purchase of property, plant and equipment</td>
<td>-102.1</td>
<td>-123.3</td>
</tr>
<tr>
<td>Proceeds on fixed asset disposals</td>
<td>6.7</td>
<td>10.0</td>
</tr>
<tr>
<td>Purchase of financial assets / Disposals of financial assets</td>
<td>-3.7</td>
<td>-14.0</td>
</tr>
<tr>
<td>Impact of changes in the scope of consolidation</td>
<td>-226.1</td>
<td>-12.3</td>
</tr>
<tr>
<td><strong>Net cash flow from (used in) investment activities</strong></td>
<td><strong>-325.2</strong></td>
<td><strong>-139.6</strong></td>
</tr>
<tr>
<td>Purchases and proceeds of treasury stocks</td>
<td>-2.8</td>
<td>-0.8</td>
</tr>
<tr>
<td>Dividends to shareholders</td>
<td>-38.7</td>
<td>-36.4</td>
</tr>
<tr>
<td>Minority interests in capital increase</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>Cost of net financial debt</td>
<td>-4.4</td>
<td>-3.2</td>
</tr>
<tr>
<td>Change in confirmed financial debt</td>
<td>-63.2</td>
<td>-6.7</td>
</tr>
<tr>
<td>Other investing cash flows</td>
<td>-1.6</td>
<td></td>
</tr>
<tr>
<td><strong>Net cash flow from (used in) financing activities</strong></td>
<td><strong>17.3</strong></td>
<td><strong>-47.4</strong></td>
</tr>
<tr>
<td>Net change in cash and cash equivalents</td>
<td>-91.3</td>
<td>12.0</td>
</tr>
</tbody>
</table>

#### Analysis of net change in cash and cash equivalents

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash and cash equivalents at the beginning of the year</td>
<td>34.0</td>
<td>14.2</td>
</tr>
<tr>
<td>Impact of currency changes on net cash and cash equivalents</td>
<td>-1.1</td>
<td>7.8</td>
</tr>
<tr>
<td><strong>Net change in cash and cash equivalents</strong></td>
<td><strong>-91.3</strong></td>
<td>12.0</td>
</tr>
<tr>
<td>Net cash and cash equivalents at the end of the year</td>
<td>-58.4</td>
<td>34.0</td>
</tr>
</tbody>
</table>
THE BIOMÉRIEUX SHARE

SHARE PRICE PERFORMANCE IN 2011*

BREAKDOWN OF CAPITAL
AS AT DECEMBER 31, 2011

THE BIOMÉRIEUX SHARE

Listed on July 6, 2004, the bioMérieux share is part of the following indexes: CAC Mid 60®, SBF 120®, CAC Mid & Small®, CAC All-tradable® and CAC All-Share®. The Company is listed on the compartment A of Eurolist and is eligible for the Deferred Settlement Service (SRD).

bioMérieux is also part of certain sustainability indexes: Gaia Index 2011/2012 and Ethibel EXCELLENCE.

At the end of December 2011, the closing price of the bioMérieux share was €55.24 and the market capitalization reached 2.2 billion euros. 18,279,447 shares were traded on the Nyse Euronext platform in 2011.

2012 CALENDAR OF EVENTS
March 13th: 2011 results
April 24th: 2012 Q1 business review
May 30th: Shareholders meeting
July 19th: 2012 Q2 business review
September 4th: 2012 first-half results
October 23rd: 2012 Q3 business review
November 29th: Investor day

INVESTOR RELATIONS CONTACT
Isabelle Tongio
Phone: 33 (0)4 78 87 22 37
Email: investor.relations@biomerieux.com

The Reference Document approved by the AMF is available upon request or on our Web site:
www.biomerieux-finance.com

* Indexes rebased on bioMérieux's stock price as at December 31, 2010 (€73.82).
**GLOSSARY**

**ANTIBIOTIC SUSCEPTIBILITY TESTING**
Determines the growth of a bacterium in the presence of antibiotics and classifies it as susceptible, resistant or intermediate.

**BIOMARKER**
Any indicator (nucleic acids, enzymes, metabolites and other types of molecules: histamines, hormones, proteins, etc.) present in the body or excreted by the body as a biological response to disease. A biomarker can make it possible to identify the presence, the effect and/or the measurement of specific phenomena, such as:
- the rapid or early detection of a disease, before the first symptoms appear,
- the progression of a disease,
- the impact of a drug or treatment.

**CHROMOGEN**
Molecule that gives off a color under certain conditions. When incorporated into a culture medium, it reveals the presence of an enzyme specific to a given bacteria, thereby indicating the bacteria that is cultured.

**CYSTICERCOSIS**
The most common parasitic infection of the central nervous system in developing countries, it is caused by the tapeworm found in pork, *Taenia solium*. In the majority of cases, infection in humans occurs when food contaminated by the tapeworm larvae is ingested. The larvae, known as *cysticerci*, spread in the body from the intestine and form cysts.

**ENUMERATION**
Counting how many microbes (bacteria or fungi) are present in a sample.

**HEALTHCARE-ASSOCIATED INFECTION (NOSOCOMIAL INFECTION)**
An infection that patients acquire during the course of receiving treatment for other conditions within a hospital or healthcare setting.

**IMMUNOASSAYS**
Detection of infectious agents (bacteria, viruses, parasites) and pathogen markers based on an antigen/antibody reaction.

**IN VITRO DIAGNOSTICS**
Analysis of biological samples (urine, blood, etc.) performed outside the human body.

**MASS SPECTROMETRY**
Technique used to identify a molecule and determine its chemical structure by analyzing the mass and the charge of its ions.

**MICROBIOLOGY**
Study of microorganisms. bioMérieux uses culture-based microbiology methods for the growth of bacteria from biological fluids, food and pharmaceutical samples. The bacteria are subsequently identified and their susceptibility to antibiotics tested in certain cases.

**MOLECULAR BIOLOGY**
Technique that can detect a bacterium, virus, yeast, parasite or a biomarker through the presence of DNA or RNA genetic sequences in a sample.

**PATHOGEN**
That which causes or can cause disease.

**PHAGE RECOMBINANT PROTEIN**
Bacteriophage tail protein that has been obtained by a biological process. Bacteriophages: highly specific viruses that only infect bacteria. They are used for the targeted capture of bacteria and to isolate them from a sample.

**SEPSIS**
A widespread infection characterized by the presence of bacteria in the bloodstream (viruses or fungi can also cause sepsis) and the deterioration of the patient’s general condition as a result of the infection (host response).

**THERANOSTICS**
The association of a diagnostic test with a therapy. The foundation of personalized medicine.
Thanks to all of the bioMérieux employees who contributed to the Annual Report photos.